Adicet Reports Third Quarter 2023 Financial Results and Prov

Initiated ADI-001 Phase 1 EXPAND cohort in post chimeric antigen receptor (CAR) T large B cell lymphoma (LBCL)Continuing to enroll mantle cell lymphoma (MCL) patients in ADI-001 Phase 1 studyPrioritizing ADI-270 for solid tumor applications; on track to file ADI-270 Investigational New Drug Application (IND) in 1H 2...

Related Keywords

, Adicet Bio , Janhavi Mohite , Chen Schor , Anne Bowdidge , International Conference On Molecular , Society For Immunotherapy Of Cancer , Drug Administration , Development For Solid Tumors , Adicet Bio Inc , Development Rd Expenses , Nasdaq , Stern Investor Relations Inc , New Drug Application , Chief Executive Officer , Operational Highlights , International Conference , Molecular Targets , Third Quarter , Private Securities Litigation Reform Act , Comprehensive Income , Investor Relations ,